Traws Pharma (TRAW) Non-Current Deffered Revenue (2012 - 2025)

Traws Pharma (TRAW) has reported Non-Current Deffered Revenue for 14 consecutive years, with $2.5 million the latest figure, recorded in Q1 2025.

• In Q1 2025, Non-Current Deffered Revenue fell 8.3% year-over-year to $2.5 million; the TTM figure through Mar 2025 stood at $2.5 million (down 8.3% YoY), while the FY2024 annual figure was $2.6 million, down 8.1% from the prior year.
• Non-Current Deffered Revenue retreated to $2.5 million in Q1 2025 per TRAW's latest filing, from $2.6 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $3.4 million in Q1 2021 and bottomed at $2.5 million in Q1 2025.
• Historically, Non-Current Deffered Revenue has averaged $3.0 million across 5 years, with a median of $3.0 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue dropped 6.21% — and 2025, when it fell 8.3%.
• Traws Pharma's Non-Current Deffered Revenue stood at $3.2 million in 2021, then decreased by 6.97% to $3.0 million in 2022, then declined by 7.49% to $2.8 million in 2023, then fell by 8.1% to $2.6 million in 2024, then declined by 2.22% to $2.5 million in 2025.
• Business Quant data shows TRAW's Non-Current Deffered Revenue at $2.5 million in Q1 2025, $2.6 million in Q4 2024, and $2.6 million in Q3 2024.